We recently compiled a list of 10 Most Undervalued Healthcare Stocks to Buy According to Analysts. Alnylam Pharmaceuticals, ...

Fintel reports that on July 21, 2025, Truist Securities initiated coverage of Alnylam Pharmaceuticals (NasdaqGS:ALNY) with a ...

Alnylam (ALNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Buying $100 In ALNY: If an investor had bought $100 of ALNY stock 15 years ago, it would be worth $2,138.15 today based on a price of $325.64 for ALNY at the time of writing.

Some genetically targeted therapies are classified in the IRA as small-molecule drugs, limiting the incentive for biotech ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $357.7, a high estimate of $404.00, and a low estimate of $325.00. Marking an increase of 10.61%, the ...

Detailed price information for Alnylam Pharmaceuticals (ALNY-Q) from The Globe and Mail including charting and trades.

Alnylam Pharmaceuticals’ Amvuttra (vutrisiran) has been approved by the Medicines and Healthcare products Regulatory Agency ...

Detailed price information for Alnylam Pharmaceuticals (ALNY-Q) from The Globe and Mail including charting and trades.

The pharmaceutical industry has a fresh sense of direction after President Donald Trump’s tax-and-spending law included a ...

On March 20, 2025, Alnylam received approval from the U.S. Food and Drug Administration (FDA) for Amvuttra to treat ATTR-CM. The approval came with a broad label that includes language about ...